Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04913337 |
|
Recruitment Status :
Recruiting
First Posted : June 4, 2021
Last Update Posted : February 10, 2023
|
Sponsor:
NGM Biopharmaceuticals, Inc
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
NGM Biopharmaceuticals, Inc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | February 2025 |
| Estimated Study Completion Date : | July 2025 |